Xeris Biopharma Holdings Inc (LTS:0A8E)

Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript

May 8, 2025 / 12:30 PM GMT

Release Date Price: $5.18 (+13.74%)

Transcript 10-Q8-K

Key Points

Positve

Xeris Biopharma Holdings Inc (XERS) reported a 48% increase in total revenue for Q1 2025, marking the 14th consecutive quarter of over 20% product revenue growth.
The company raised the bottom end of its revenue guidance from $255 million to $260 million, indicating confidence in continued growth.
Rekorolev, XERS's fastest-growing product, saw a 141% increase in revenue, driven by targeted investments in patient access and healthcare provider engagement.
The FDA approved XERS's supplemental new drug application for GVO vileDX, expanding its use as a diagnostic aid during radiologic examinations.
XERS maintains a strong financial position, allowing for strategic growth without the need for dilutive financing, and achieved a positive adjusted EBITDA of $4.4 million for the quarter.

Negative

Despite strong growth, XERS did not provide updated guidance on peak sales potential for Rekorolev, leaving some uncertainty about future revenue ceilings.
The company faces competitive pressures in the glucagon market, although it claims to be driving market growth.
Selling, general, and administrative expenses increased by 15% compared to the prior year, reflecting higher costs associated with commercial expansion.
There is ongoing speculation about potential sector-specific tariffs, although XERS does not anticipate a material impact due to its US-centric operations.
XERS's future growth is partly dependent on the successful development and commercialization of new products like XP 8,121, which still requires further development and regulatory approval.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

XERS.OQ - Xeris Biopharma Holdings Inc
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call
May 08, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning.

Thank you for attending today's Zero former first quarter 2025 results conference call. My name is Makaya, and I'll be the moderator for today's call. All lines will be muted in the presentation portion of the call with an opportunity for your questions and answers at the end. At this time, I'd like to pass the call over to our senior Vice President of investor relations and corporate communications, Allison.

Allison, you may proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Mathias. Good morning, everyone. We

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.